

**MAILING CERTIFICATE**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on  
March 6, 2007 by Ray Butler Ray Butler (print name)  
Date Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Zeiher et al.

Filing Date: October 13, 2004

Application No.: 10/574,380

For: IN VITRO METHOD FOR THE DIAGNOSIS OF CARDIOVASCULAR  
FUNCTIONALITY OF BONE MARROW-PRECURSOR CELLS (BMPs) AND/OR  
BLOOD-DERIVED CIRCULATING PRECURSOR CELLS (BDPs)

Docket: 81197-2

Date: March 5, 2007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:


Pursuant to the obligation recited in 37 C.F.R. § 1.56 and in conformance with 37 C.F.R. §§ 1.97-1.98, Applicants request consideration of this Information Disclosure Statement in prosecution of this application. Pursuant to 37 C.F.R. § 1.97(b), no fee or certification is required because this Statement is filed within three months of the filing date of the application or before the mailing date of a first Office Action on the merits, whichever event occurs last.

Applicants cite four references listed on the attached form substitute Form PTO-1449. A copy of the cited reference is enclosed for the Examiner's review. The Examiner is encouraged to review the references in order to draw his or her own conclusions concerning the pertinence of the reference to the claimed subject matter of this application. The filing of this Information Disclosure

Statement should not be construed to suggest that a patentability search has been made or that the cited references are prior art or are considered to be material to patentability.

These references were cited in the International Preliminary Examination Report of the international patent application from which it derives. A copy of the Examination Report is also enclosed.

Respectfully submitted,



Barry L. Davison, P.D., J.D.  
Attorney for Applicants  
Registration No. 47,309

Davis Wright Tremaine LLP  
2600 Century Square  
1501 Fourth Avenue  
Seattle, WA 98101-1688  
Tel 206-628-7621  
Fax 206-628-7699

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/574,380
		Filing Date	October 13, 2004
		First Named Inventor	Zelher
		Art Unit	
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	81197-2

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

81

-6- 1 9

---

**U.S. PATENT DOCUMENTS**

---

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>4</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>5</sup> Applicant's unique citation designation number (optional).<sup>6</sup> See Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.03.<sup>7</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).<sup>8</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible.<sup>9</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

IF YOU ARE SENDING A FAX, FAX THE FORM TO THIS ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1400, Alexandria, VA 22314-1400. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number

10/574,380

Filing Date

October 13, 2004

First Named Inventor

Zeiher

Art Unit

Examiner Name

Attorney Docket Number

81197-2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	O1	VASA, M. et al., Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease, "Circulation Research 89(1): E1-E7 , 2001	
	O2	YAMAGUCHI, J.-I. et al., Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization, "Circulation 107(9) 1322-1328 , 2003	
	O3	ASSMUS, B. et al., Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI), Circulation 106(24) 3009-3017 , 2002	
	O4	KIM, C.H. et al., In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived Factor-1, steel factor, and the bone marrow environment, Blood 91(1), 100-110 , 1998	

Examiner Signature	/Michail Belyavskyi/	Date Considered	02/26/10
--------------------	----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.